Clinical implementation of noninvasive prenatal testing among maternal fetal medicine specialists

Prenatal Diagnosis

Volumn 34, Issue 5, 2014, Pages 416-423

  Haymon, Lori ^a   Simi, Eve ^b   Moyer, Kelly ^c   Aufox, Sharon ^a   Ouyang, David W ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AMNIOCENTESIS; ANEUPLOIDY; ANXIETY; ARTICLE; CHORION VILLUS SAMPLING; CHROMOSOME ABERRATION; CLINICAL PRACTICE; COST; DOWN SYNDROME; E-MAIL; FEMALE; FETUS ECHOGRAPHY; HEALTH INSURANCE; HIGH RISK PATIENT; HUMAN; LIKERT SCALE; MALE; MATERNAL AGE; MATERNAL FETAL MEDICINE SPECIALIST; MEDICAL SPECIALIST; NON INVASIVE PRENATAL TESTING; NON INVASIVE PROCEDURE; NORMAL HUMAN; NUCHAL TRANSLUCENCY MEASUREMENT; PATIENT COUNSELING; PATIENT PREFERENCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRENATAL SCREENING; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE; RHESUS ISOIMMUNIZATION; SENSITIVITY ANALYSIS; TREATMENT INDICATION; TRISOMY 18; TRISOMY 21; ATTITUDE TO HEALTH; HEALTH CARE PLANNING; HEALTH SERVICE; HEALTH SURVEY; MEDICINE; MIDDLE AGED; PREGNANCY; PRENATAL DIAGNOSIS; STATISTICS AND NUMERICAL DATA;

FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH PLAN IMPLEMENTATION; HEALTH SURVEYS; HUMANS; MALE; MATERNAL HEALTH SERVICES; MEDICINE; MIDDLE AGED; PREGNANCY; PRENATAL DIAGNOSIS; QUESTIONNAIRES;

EID: 84898818104     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4301     Document Type: Article

References (49)

1. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485-7.
2. Bianchi DW, Platt LD, Goldberg JD, et al. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol 2012;119(5):890-901.
3. Chen EZ, Chiu RW, Sun H, et al. Noninvasive prenatal diagnosis of fetal trisomy 18 and trisomy 13 by maternal plasma DNA sequencing. PLoS One 2011;6(7):e21791.
4. Ehrich M, Deciu C, Zwiefelhofer T, et al. Noninvasive detection of fetal trisomy 21 by sequencing of DNA in maternal blood: a study in a clinical setting. Am J Obstet Gynecol 2011;204(3):205 e201-211.
5. Norton ME, Brar H, Weiss J, et al. Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;207(2): 137 e131-138.
6. Palomaki GE, Kloza EM, Lambert-Messerlian GM, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 2011;13(11):913-20.
7. Palomaki GE, Deciu C, Kloza EM, et al. DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study. Genet Med 2011;14(3):296-305.
8. Sehnert AJ, Rhees B, Comstock D, et al. Optimal detection of fetal chromosomal abnormalities by massively parallel DNA sequencing of cell-free fetal DNA from maternal blood. Clin Chem 2011;57(7):1042-9.
9. Sparks AB, Wang ET, Struble CA, et al. Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy. Prenat Diagn 2012;32(1):3-9.
10. Sparks AB, Struble CA, Wang ET, et al. Noninvasive prenatal detection and selective analysis of cell-free DNA obtained from maternal blood: evaluation for trisomy 21 and trisomy 18. Am J Obstet Gynecol 2012;206(4): 319 e311-319.
11. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. Prenat Diagn 2012;32(13):1233-41.
12. Allyse M., Sayres LC, King JS, et al. Cell-free fetal DNA testing for fetal aneuploidy and beyond: clinical integration challenges in the US context. Hum Reprod 2012;27(11):3123-31.
13. American College of Obstetrics and Gynecology (ACOG). Committee Opinion No. 545: noninvasive prenatal testing for fetal aneuploidy. Obstet Gynecol 2012;120(6):1532-4.
14. Nicolaides KH, Syngelaki A, Ashoor G, et al. Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population. Am J Obstet Gynecol 2012;207(5):374 e371-76. [Correction made here after initial online publication.]
15. Hill M, Barrett AN, White H, Chitty LS. Uses of cell free fetal DNA in maternal circulation. Best Pract Res Clin Obstet Gynaecol 2012;26(5):639-54.
16. Lun FM, Tsui NB, Chan KC, et al. Noninvasive prenatal diagnosis of monogenic diseases by digital size selection and relative mutation dosage on DNA in maternal plasma. Proc Natl Acad Sci U S A 2008;105(50):19920-5.
17. Jensen TJ, Dzakula Z, Deciu C, et al. Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma. Clin Chem 2012;58(7):1148-51.
18. Hui L, Bianchi DW. Recent advances in the prenatal interrogation of the human fetal genome. Trends Genet 2013;29(2):84-91.
19. Lo YM, Chan KC, Sun H, et al. Maternal plasma DNA sequencing reveals the genome-wide genetic and mutational profile of the fetus. Sci Transl Med 2010;2(61):61ra91.
20. Daniels G, Finning K, Martin P, Massey E. Review: noninvasive prenatal diagnosis of fetal blood group phenotypes: current practice and future prospects. Prenat Diagn 2009;29:101-7.
21. Benn PA, Chapman AR. Ethical challenges in providing noninvasive prenatal diagnosis. Curr Opin Obstet Gynecol 2010;22:128-34.
22. Chachkin CJ. What potent blood: non-invasive prenatal genetic diagnosis and the transformation of modern prenatal care. Am J Law Med 2007;33(1):9-53.
23. Greely HT. Get ready for the flood of fetal gene screening. Nature 2011;469(7330):289-91. [Correction made here after initial online publication.]
24. Haymon L. Noninvasive Prenatal Diagnosis. [Internet]. Cambridge (MA): CRG Special Report (US); 2011 [cited 2013 Apr 3]. Available from: http://www.councilforresponsiblegenetics.org/
25. Mozersky J, Mennuti MT. Cell-free fetal DNA testing: who is driving implementation? Genet Med 2012;15(6):433-4.
26. Sayres LC, Allyse M, Cho MK. Integrating stakeholder perspectives into the translation of cell-free fetal DNA testing for aneuploidy. Genome Med 2012;4(6):49.
27. Schmitz D, Netzer C, Henn W. An offer you can't refuse? Ethical implications of non-invasive prenatal diagnosis. Nat Rev Genet 2009;10(8):515.
28. Tischler R, Hudgins L, Blumenfeld YJ, et al. Noninvasive prenatal diagnosis: pregnant women's interest and expected uptake. Prenat Diagn 2011;31(13):1292-9. (Surveyed patients regarding their hypothetical responses to positive NIPT results, finding statistically significant differences on choosing to confirm by invasive procedures based solely on the information given about NIPT).
29. Sayres LC, Allyse M, Norton ME, Cho MK. Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation. Prenat Diagn 2011;31(11):1070-6.
30. What is Maternal Fetal Medicine Page [Internet]. Washington DC: Society of Maternal Fetal Medicine 2002 [cited 2013 April 3]. Available from:/www.smfm.org.
31. MarketWatch.com. Sequenom Announces Preliminary 2012 Operational Highlights [Internet]. San Diego:PRNewswire; Jan 6, 2013 [cited November 2012]. Available from: http://www.prnewswire.com (quoting Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom).
32. Driscoll DA, Morgan MA, Schulkin J. Screening for Down syndrome: changing practice of obstetricians. Am J Obstet Gynecol 2009;200(4): 459 e451-459.
33. ISPD Rapid Response Statement: Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis, 24 October 2011.
34. Devers PL, Cronister A, Ormond KE, et al. Noninvasive Prenatal Testing/Noninvasive Prenatal Diagnosis: the Position of the National Society of Genetic Counselors. J Genet Couns 2013;22(3):291-5.
35. Gregg AR, Gross SJ, Best RG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med 2013;15(5):395-8.
36. Androutsopoulos G, Gkogkos P, Decavalas G. Mid-trimester maternal serum HCG and alpha fetal protein levels: clinical significance and prediction of adverse pregnancy outcome. Int J Endocrinol Metab 2013;11(2):102-6.
37. Gagnon A, Wilson RD, Auidbert F, et al. Obstetrical complications associated with abnormal maternal serum markers analytes. J Obstet Gynaecol Can 2008;30(10):918-49.
38. Pahal GS, Jauniaux E. Maternal serum biochemical screening for pregnancy complications other than aneuploidy. Curr Opin Obstet Gynecol 1997;9(6):379-86.
39. Genomeweb.com. ACOG Issues Favorable Opinion for Non-invasive Prenatal Test Makers [Internet]. New York: GenomewebLLC; November 21, 2012 [cited November 2012]. Available from: http://www.genomeweb.com.
40. UnitedHealthcare. Noninvasive Prenatal Diagnosis of Fetal Aneuploidy Using Cell-Free Fetal Nucleic Acids in Maternal Blood. Policy number: 2013T0560B, April 2013.
41. Aetna. Clinical Policy Bulletin: Serum Marker Screening for Down Syndrome. Policy number: 0464, February 2013.
42. Genomeweb.com. UnitedHealthcare Joins List of National Payors Supporting Non-invasive Prenatal Diagnostic Testing [Internet]. New York: GenomewebLLC; March 05, 2013 [cited 26 December 2013]. Available from: http://www.genomeweb.com.
43. See Hayden E. Fetal tests spur legal battle: a newborn industry based on non-invasive genetic testing turns combative. Nature [Internet] 2012;486:454-5 (discussing many factors that impact cost and coverage of NIPT, including state-based medicaid coverage only for testing by particular test providers).
44. Ashoor G, Poon L, Syngelaki A, et al. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks' gestation: effect of maternal and fetal factors. Fetal Diagn Ther 2012;31(4):237-43.
45. Agarwal A, Sayres LC, Cho MK, et al. Commercial landscape of noninvasive prenatal testing in the United States. Prenat Diagn 2013;33:521-31.
46. Sequenom.com. Maternti21Plus 2013 [February 4, 2013]. Available from: http://www.sequenomcmm.com/Home/Health-Care-Professionals/Trisomy-21.
47. Deutsch AB, Duncan K, Rajaram L, et al. Cesarean or vaginal delivery for the breech fetus at the threshold of viability: results from a maternal-fetal medicine specialists survey. J Matern Fetal Neonatal Med 2011;24(3):475-9.
48. Healy AJ, Veille JC, Sciscione A, et al. The timing of elective delivery in preterm premature rupture of the membranes: a survey of members of the Society of Maternal-Fetal Medicine. Am J Obstet Gynecol 2004;190(5):1479-81.
49. Kerns JL, Steinauer JE, Rosenstein MG, et al. Maternal-fetal medicine subspecialists' provision of second-trimester termination services. Am J Perinatol 2012;29(9):709-16.